combine@alvar.ug

Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa

Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa

Show simple record

dc.contributor.author Petersen, Maya
dc.contributor.author Balzer, Laura
dc.contributor.author Kwarsiima, Dalsone
dc.contributor.author Sang, Norton
dc.contributor.author Chamie, Gabriel
dc.contributor.author Ayieko, James
dc.contributor.author Kabami, Jane
dc.contributor.author Owaraganise, Asiphas
dc.contributor.author Liegler, Teri
dc.contributor.author Mwangwa, Florence
dc.contributor.author Kadede, Kevin
dc.contributor.author Jain, Vivek
dc.contributor.author Plenty, Albert
dc.contributor.author Brown, Lillian
dc.contributor.author Lavoy, Geoff
dc.contributor.author Schwab, Joshua
dc.contributor.author Black, Douglas
dc.contributor.author van der Laan, Mark
dc.contributor.author Bukusi, Elizabeth A.
dc.contributor.author Cohen, Craig R.
dc.contributor.author Clark, Tamara D.
dc.contributor.author Charlebois, Edwin
dc.contributor.author Kamya, Moses
dc.contributor.author Havlir, Diane
dc.date.accessioned 2021-01-01T21:58:21Z
dc.date.available 2021-01-01T21:58:21Z
dc.date.issued 2017
dc.identifier.issn 0098-7484
dc.identifier.uri http://combine.alvar.ug/handle/1/48277
dc.description.abstract IMPORTANCE Antiretroviral treatment (ART) is now recommended for all HIV-positive persons. UNAIDS has set global targets to diagnose 90% of HIV-positive individuals, treat 90% of diagnosed individuals with ART, and suppress viral replication among 90% of treated individuals, for a population-level target of 73% of all HIV-positive persons with HIV viral suppression. OBJECTIVE To describe changes in the proportions of HIV-positive individuals with HIV viral suppression, HIV-positive individuals who had received a diagnosis, diagnosed individuals treated with ART, and treated individuals with HIV viral suppression, following implementation of a community-based testing and treatment program in rural East Africa. DESIGN, SETTING, AND PARTICIPANTS Observational analysis based on interim data from 16 rural Kenyan (n = 6) and Ugandan (n = 10) intervention communities in the SEARCH Study, an ongoing cluster randomized trial. Community residents who were 15 years or older (N = 77 774) were followed up for 2 years (2013-2014 to 2015-2016). HIV serostatus and plasma HIV RNA level were measured annually at multidisease health campaigns followed by home-based testing for nonattendees. All HIV-positive individuals were offered ART using a streamlined delivery model designed to reduce structural barriers, improve patient-clinician relationships, and enhance patient knowledge and attitudes about HIV. MAIN OUTCOMES AND MEASURES Primary outcome was viral suppression (plasma HIV RNA <500 copies/mL) among all HIV-positive individuals, assessed at baseline and after 1 and 2 years. Secondary outcomes included HIV diagnosis, ART among previously diagnosed individuals, and viral suppression among those who had initiated ART. RESULTS Among 77 774 residents (male, 45.3%; age 15-24 years, 35.1%), baseline HIV prevalence was 10.3%(7108 of 69 283 residents). The proportion of HIV-positive individuals with HIV viral suppression at baseline was 44.7%(95% CI, 43.5%-45.9%; 3464 of 7745 residents) and after 2 years of intervention was 80.2%(95% CI, 79.1%-81.2%; 5666 of 7068 residents), an increase of 35.5 percentage points (95% CI, 34.4-36.6). After 2 years, 95.9% of HIV-positive individuals had been previously diagnosed (95% CI, 95.3%-96.5%; 6780 of 7068 residents); 93.4% of those previously diagnosed had received ART (95% CI, 92.8%-94.0%; 6334 of 6780 residents); and 89.5% of those treated had achieved HIV viral suppression (95% CI, 88.6%-90.3%; 5666 of 6334 residents). CONCLUSIONS AND RELEVANCE Among individuals with HIV in rural Kenya and Uganda, implementation of community-based testing and treatment was associated with an increased proportion of HIV-positive adults who achieved viral suppression, along with increased HIV diagnosis and initiation of antiretroviral therapy. In these communities, the UNAIDS population-level viral suppression target was exceeded within 2 years after program implementation.
dc.description.sponsorship National Institute of Allergy and Infectious Diseases at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069502, U01AI099959, R01AI074345]
dc.description.sponsorship US President's Emergency Plan for AIDS ReliefUnited States Agency for International Development (USAID)
dc.description.sponsorship Office of the Global AIDS Coordinator
dc.description.sponsorship Gilead Sciences (Truvada donation)
dc.description.sponsorship Office of AIDS ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA
dc.description.sponsorship University of California, San Francisco-Gladstone Institute of Virology and Immunology Center for Aids ResearchUniversity of California System [P30 AI027763]
dc.description.sponsorship NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI074345, R01AI074345, R01AI074345, R01AI074345, R01AI074345, UM1AI069502, R01AI074345, R01AI074345, UM1AI069502, R01AI074345, R01AI074345, R01AI074345] Funding Source: NIH RePORTER
dc.description.sponsorship NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246] Funding Source: NIH RePORTER
dc.language English
dc.publisher AMER MEDICAL ASSOC
dc.relation.ispartof JAMA-Journal of the American Medical Association
dc.title Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa
dc.type Article
dc.identifier.isi 000402706100016
dc.identifier.doi 10.1001/jama.2017.5705
dc.identifier.pmid 28586888
dc.publisher.city CHICAGO
dc.publisher.address 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
dc.identifier.eissn 1538-3598
dc.identifier.volume 317
dc.identifier.issue 21
dc.identifier.spage 2196
dc.identifier.epage 2206
dc.subject.wc Medicine, General & Internal
dc.subject.sc General & Internal Medicine
dc.description.oa Green Published
dc.description.pages 11
dc.subject.kwp Care
dc.subject.kwp Art
dc.subject.kwp Retention
dc.subject.kwp Infection
dc.subject.kwp Cascade
dc.subject.kwp Rna
dc.description.affiliation Univ Calif Berkeley, Sch Publ Hlth, 101 Haviland Hall, Berkeley, CA 94110 USA
dc.description.affiliation Univ Calif San Francisco, San Francisco, CA 94143 USA
dc.description.affiliation Harvard TH Chan Sch Publ Hlth, Boston, MA USA
dc.description.affiliation Infect Dis Res Collaborat, Kampala, Uganda
dc.description.affiliation Kenya Govt Med Res Ctr, Nairobi, Kenya
dc.description.affiliation Makerere Univ, Kampala, Uganda
dc.description.email mayaliv@berkeley.edu
dc.description.corr Petersen, M (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, 101 Haviland Hall, Berkeley, CA 94110 USA.
dc.description.orcid Asiphas, Owaraganise/0000-0002-5594-0310


This record appears in the collections of the following institution(s)

Show simple record

Search Entire Database


Browse

My Account